Pentoxifylline for diabetic kidney disease: how much do we actually know?
Nephrology Dialysis Transplantation · 22.10.2026
DOI: 10.1093/ndt/gfag244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.10.2026. Verfasst von Rajiv Agarwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, IN. Die Arbeit nennt 31 Literaturangaben. Gefördert von: VA Cooperative Studies Program.
Abstract (Originalsprache)
Background and hypothesis Pentoxifylline is an inexpensive anti-inflammatory agent tested in diabetic kidney disease for four decades; prior meta-analyses report reduced albuminuria. Whether this effect is reliable, extends to kidney function, or reaches hard outcomes is unclear; we hypothesized the surrogate evidence might be conclusive and the hard-outcome evidence not.
Methods
We reviewed randomized trials of oral pentoxifylline in diabetic kidney disease to June 2026, without language restriction. Co-primary surrogate outcomes were albuminuria (ratio of means) and glomerular filtration rate (GFR) change (mean difference); the primary hard outcome was end-stage kidney disease or death (risk ratio). We pooled with random-effects models, assessed risk of bias with RoB 2, and report a prediction interval and trial sequential analysis with every estimate.
Results
Thirty-four studies were included, 32 contributing data. Albuminuria fell by about one-third [ratio of means 0.69, 95% confidence interval 0.50–0.94; 22 studies contributing 23 comparisons], but heterogeneity was extreme (I2 97%), the prediction interval 0.15–3.10, and only 53% of the required information had accrued, with no boundary crossed. Over ≥12 months, GFR changed 4.49 ml/min/1.73 m2 more favorably with pentoxifylline than with control (0.84–8.14; five studies contributing five comparisons); in two trials at low or some-concerns risk of bias it was 2.96 (−15.34 to 21.26), with 11% of the required information accrued. For end-stage kidney disease or death, 29 events in 6 studies contributing 7 comparisons gave a risk ratio of 0.90 (0.46–1.77), 3% of that required. Gastrointestinal adverse events were three times as common (3.00, 1.94–4.64); serious ones were not (0.83, 0.56–1.22).
Conclusions
Pentoxifylline reduces albuminuria, but the effect is heterogeneous, depends on which trials are counted, and may not reappear in a new trial. Kidney failure and death have scarcely been tested. The priority is an adequately powered, long-term trial reporting hard endpoints; gastrointestinal intolerance should be anticipated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, IN.
- Edward Hines, Jr VA Hospital, Hines, IL.
- Michael E. DeBakey VA Medical Center, Houston, TX.
- VA Puget Sound Health Care System, Seattle, WA.
- Hines VA Cooperative Studies Program Coordinating Center, Hines, IL.
ORCID-Profile: Rajiv Agarwal, David J Leehey, Sankar D Navaneethan
Förderung
- VA Cooperative Studies Program
Zitieren
APA
Agarwal, R., Leehey, D. J., Navaneethan, S. D., Utzschneider, K. M., Xing, B., & Carlson, K. (2026). Pentoxifylline for diabetic kidney disease: how much do we actually know?. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag244
Vancouver
Agarwal R, Leehey DJ, Navaneethan SD, Utzschneider KM, Xing B, Carlson K. Pentoxifylline for diabetic kidney disease: how much do we actually know?. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag244
BibTeX
@article{Agarwal2026,
author = {Agarwal, Rajiv and Leehey, David J and Navaneethan, Sankar D and Utzschneider, Kristina M and Xing, Bin and Carlson, Kimberly},
title = {Pentoxifylline for diabetic kidney disease: how much do we actually know?},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag244}
}
EUVIMED